Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

BACKGROUND: Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real‐world data of ALK TKIs remain a major concern. METHODS: Patients with ALK‐positive advanced NSCLC, who received cri...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yurong, Shen, Shujing, Hu, Peizhu, Geng, Di, Zheng, Ruipan, Li, Xingya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741982/
https://www.ncbi.nlm.nih.gov/pubmed/35616090
http://dx.doi.org/10.1002/cam4.4834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741982/
https://www.ncbi.nlm.nih.gov/pubmed/35616090
http://dx.doi.org/10.1002/cam4.4834

Ejemplares similares